Trending...
- THE OIL TRUTH: They Never Wanted Us To Remember: How Engineered Scarcity Kept America In Chains For Generations
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- ExtriCARE USA, a national medical device company specializing in negative pressure wound therapy (NPWT) distribution, is excited to introduce hybrid technology to the wound care market.
The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.
ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.
More on The PennZone
Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.
ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.
"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."
When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.
More on The PennZone
ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.
For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].
About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.
SOURCE ExtriCARE USA
Related Links
https://extricareusa.com
The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.
ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.
More on The PennZone
- Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.
ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.
"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."
When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.
More on The PennZone
- Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
- Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
- "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
- Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
- World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.
For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].
About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.
SOURCE ExtriCARE USA
Related Links
https://extricareusa.com
0 Comments
Latest on The PennZone
- Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
- Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
- Vegan Chef KESS Celebrates Parade.com Feature and Expands Into Wedding Catering
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- Benchmark International Facilitated the Trans of P&Ro Solutions Group and FOCUS Learning Corporation
- Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
- JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
- Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- YWCA Hanover to Host Ribbon Cutting for New Children's Learning Academy
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- THE OIL TRUTH: They Never Wanted Us To Remember: How Engineered Scarcity Kept America In Chains For Generations
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research